ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

ישראל - עברית - Ministry of Health

megapharm ltd - anakinra - תמיסה להזרקה - anakinra 150 mg/ml - anakinra - anakinra - kineret is indicated for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone.

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen plus u.v (puva).

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab

ישראל - עברית - Ministry of Health

neopharm (israel) 1996 ltd - rilonacept - אבקה מיובשת בהקפאה להכנת תמיסה להזרקה - rilonacept 80 mg/ml - rilonacept

ישראל - עברית - Ministry of Health

neopharm (israel) 1996 ltd - rilonacept - אבקה מיובשת בהקפאה להכנת תמיסה להזרקה - rilonacept 80 mg/ml - rilonacept